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Impact of Diabetes Mellitus on Angiographic Outcomes in Patients with Different
Drug-eluting Stents
Seiji Habara1, Kazushige Kadota1, Hiroyuki Tanaka1, Yasushi Fuku1,
Tsuyoshi Goto1, Kazuaki Mitsudo1
1Kurashiki Central Hospital, Kurashiki, Japan
Background: There is currently no data to evaluate the differences of drug-eluting
stents on the angiographic outcomes of diabetes mellitus (DM) patients. To evaluate
the effects of different drug-eluting stents on the outcomes of DM patients, we
investigated serial angiographic outcomes after drug-eluting stent placement.
Methods: From 2002 to 2012, 10983 consecutive de-novo coronary lesions were
treated using drug-eluting stents (biolimus-eluting stent (BES); n¼1367, everolimus-
eluting stent (EES); n¼2983, paclitaxel-eluting stent (PES); n¼1215, sirolimus-
eluting stent (SES); n¼5418). 41% were DM and 10% were insulin-treated patients.
Angiographic follow-up was routinely performed 8 months after a successful proce-
dure (follow-up rate was 82%). Angiographic outcomes were compared among pa-
tients with the implanted stent types.
Results: The binary restenosis rates were 6.6% in non-DM patients, 11.0% in non-
insulin-requiring DM patients, and 14.0% in insulin-treated DM patients. The SES,
PES and BES groups had higher restenosis rates in non-insulin-requiring DM patients
compared with non-DM patients (SES; 6.1% vs. 10.4%, p< 0.001, PES; 12.0% vs.
21.7%, p< 0.001, BES 5.9% vs. 9.1%, p¼0.04). Binary restenosis in the EES group
were similar between non-DM patients and non-insulin-requiring DM patients (5.5%
vs. 5.6%, p¼0.92). A multivariable analysis showed that DM was an independent
predictor of recurrent restenosis in implantation of SES (odds ratio [OR]: 1.98, 95%
conﬁdence interval [CI]: 1.59 to 2.46, p< 0.001), PES (OR: 1.74, CI: 1.22 to 2.48,
p¼0.002), and BES (OR: 1.60, CI: 1.01 to 2.53, p¼0.04), except EES (OR: 1.19, CI:
0.85 to 1.67, p¼0.30).
Conclusions: Percutaneous coronary intervention in DM patients is associated with
worse angiographic outcomes compared with those in non-DM patients. The use of
EES could be effective for DM patients.
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Background: To evaluate whether the impact on clinical outcomes of newer vs. ﬁrst
generation drug-eluting stents (DES) is inﬂuenced by diabetes mellitus (DM).
Methods: We pooled patient-level data of 10,448 women undergoing PCI with DES
from 26 randomized trials. Baseline characteristics and long-term clinical outcomes
were stratiﬁed according to baseline DM status and DES type (new vs. ﬁrst genera-
tion). Associations between stent type and outcomes were examined within each
stratum using Cox regression with trial entered as a random effect. The primary
endpoint was the composite of all-cause death and myocardial infarction (MI). Sec-
ondary endpoints were target-lesion revascularization (TLR) and deﬁnite or probable
stent thrombosis (ST).
Results: DM was present in 3,294 (31.5%) of women treated with DES. In women
without DM, use of new generation compared with ﬁrst generation DES was asso-
ciated with reduced risks of death or MI (7.6% vs. 10.2%; adjHR 0.69, 95%CI, 95%CI
0.55-0.88), ST (0.8% vs. 1.7%; adjHR 0.32, 95%CI 0.17-0.62) and TLR (5.3% vs.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Li6.9%; adjHR 0.74, 95%CI 0.56-0.99). No major differences were observed between
new and ﬁrst generation DES for death or MI (12.8% vs. 12.4%; adjHR 0.90, 95%CI,
95%CI 0.69-1.19), ST (2.0% vs. 3.1%; adjHR 0.84, 95%CI 0.47-1.49) and TLR
(8.7% vs. 9.5%; adjHR 1.14, 95%CI 0.82-1.59) among women with DM (Figure).
Interaction testing was signiﬁcant for the outcome of def/prob ST (p¼0.04).
Supporting File(s)
Location: https://ww5.aievolution.com/tct2014/ﬁles/content/abstracts/abs_1716/
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Conclusions: The safety and efﬁcacy proﬁle of new generation compared with ﬁrst
generation DES among women varies according to the presence of DM with enhanced
beneﬁts in women without DM.
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Background: It is still unknown whether different stent types of new-generation
cobalt-chromium drug-eluting stent (DES) correlate with clinical outcomes in patients
with diabetes.
Methods: Across 2 Italian centers, we retrospectively evaluated the primary endpoint
of major adverse cardiac events (MACE) amongst patients receiving new-generation
zotarolimus-eluting stents (ZES: Resolute family [Medtronic, Santa Rosa, CA]) and
everolimus-eluting stents (EES: Xience family [Abbott Vascular, Santa Clara, CA]
and PROMUS stent [Boston Scientiﬁc, Natick, MA]). Secondary endpoints included
the composite endpoint of all-cause mortality and any myocardial infarction (MI), and
any target lesion revascularization (TLR).
Results: Four hundred patients with 553 coronary lesions treated with ZES (136
patients, 196 lesions) and EES (264 patients, 357 lesions) between October 2006 and
August 2012 were included in the present study. Patient demographics and other
cardiovascular risk factors were similar between the two groups. Multi-vessel PCI
(23.5% vs. 14.0%, p¼0.017), a PCI for restenotic lesion (26.0% vs. 15.4%, p¼0.002),
IVUS usage (30.1% vs. 17.4%, p¼0.001) were signiﬁcantly higher in the ZES group,
whereas implantation of smaller vessel stents (2.5mm) was statistically higher in the
EES group (27.6% vs. 37.8%, p¼0.015). At the follow-up period of 720 days, there
was no signiﬁcant difference in MACE between ZES and EES (22.8% vs. 18.1%,
HR¼1.11, 95%CI: 0.67-1.85). Similarly no signiﬁcant differences were observed in
the composite endpoint of death or MI (9.1% vs. 10.3%, HR¼1.14, 95%CI: 0.54-
2.40) or TLR (12.4% vs. 6.9%, HR¼1.53, 95%CI; 0.81-2.89).
Conclusions: The present study showed that no signiﬁcant differences in each outcomes
(MACE, all-cause mortality/MI, TLR) were observed in diabetic patients treated with
new-generation cobalt-chromium ZES and EES. Even though, our study cohort
constituted of more complex lesions and patient characteristics, our ﬁndings resemble
the ones reported in previous randomized control studies in the general population.Lipid Disorders and Management
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Effects of Pitavastatin on the Expression of Vascular Cell Adhesion Molecule-1
and Its Target Gene MicroRNA-126 in Cultured Human Umbilical Vein
Endothelial Cell
Qinglu Xu1, Tianzhu Luan1, Songbin Fu2
1The First Afﬁliated Hospital of Harbin Medical University, Harbin, Heilongjiang,
2Harbin Medical University, Harbin, Heilongjiang
Background: Reducing the expression of endothelial cell adhesion molecules
(ECAMs) is conducive to the decrease of inﬂammation-induced vascular complica-
tions. In this study, we observed Pitavastatin on the expression of vascular cell
adhesion molecule-1 (VCAM-1) and its inﬂuence on VCAM-1’s target gene miR-126
in cultured human umbilical vein endothelial cells (HUVEC) activated by tumor
ncrosis factor-a (TNF-a). The purpose of this study is to explore the mechanism of
pitavastatin in prevention and treatment of atherosclerosis (AS).
Methods: HUVEC were cultured in M1640 supplemented with 10% bovine calf serum
and passages 2 to 5were used in experiments. The cells were randomly divided into threepid Disorders and Management B73
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comgroups, control, TNF-a and pitavastatin group. Cells of TNF-a group were co-incubated
with different concentrations（10mg/L，20mg /L，30mg /L）ofTNF-a for 24h.Cells of
pitavastatin group were ﬁrstly coincubated with 0.01, 0.1, 1mmol/L pitavastatin
respectively for 1h, then coincubated with 30mg/L TNF-a for 24h. VCAM -1 and miR-
126 mRNA were detected by quantitative reverse transcription polymerase chain reac-
tion (RT-PCR) andWestern blotting was used to detect protein expression of VCAM-1.
Results: Both detection methods have showed that TNF-a stimulation signiﬁcantly
induced the mRNA and protein expression of VCAM-1 in HUVECs in a dose-
dependent manner, and miR-126 mRNA expression exhibited a decreasing trend when
cultured with TNF-a. The increase of VCAM-1 mRNA and protein expression
induced by TNF-a was inhibited by pitavastatin in a dose-dependent manner, too.
However, there were no differences of the expression of miR-126 among three groups.
Conclusions: These effects may explain the ability of pitavastatin to reduce the
progression of atherosclerosis and may increase the stability of plaques. The ﬁndings
further suggest that inhibitory effect of pitavastatin on VCAM-1 is not related to miR-
126 but depends on other things.Characteristic
Odds Ratio
(95% CI) p-value
History of Diabetes Mellitus 1.7 (1.3, 2.2) <0.001
History of CHF 1.6 (1.3, 2.1) <0.001
History of prior CABG 0.7 (0.5, 0.9) 0.007
Low BMI < 18 3.3 (1.2, 9.1) 0.024
High BMI > 30 4.3 (1.5, 12.1) 0.006
Pre-PVI Anemia 2 (1.5, 2.5) <0.001
Creatinine Clearance < 30 ml/min 2.5 (1.8, 3.6) <0.001
Critical Limb Ischemia 1.6 (1.2, 2.1) 0.001
Status – Urgent 2.9 (2.2, 3.7) <0.001
Status – Emergent 7.1 (4.4, 11.4) <0.001
Contrast volume (ml) > 3 x Creatinine Clearance (ml/ 1.5 (1.1, 1.9) 0.003Renal Insufﬁciency and Contrast Nephropathy
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Preprocedural Statin Administration Beneﬁt According To Baseline Renal
Function: A MetaLAnalysis Of Randomized Controlled Trials
Daniele Giacoppo1, Davide Capodanno1, Piera Capranzano1, Patrizia Aruta1,
Corrado Tamburino1
1Ferrarotto Hospital, Catania, Italy
Background: Preprocedural statin administration seems to reduce contrast–induced
acute kidney injury (CI–AKI). This beneﬁt, however, might be limited to patients
without advanced chronic kidney disease.
Methods: Randomized controlled trials (RCTs) comparing preprocedural statin
administration before coronary catheterization with standard strategies were searched
in MEDLINE/PubMed, Embase, Scopus, Web of Science, and ScienceDirect data-
bases. Patients were stratiﬁed in two groups according to a glomerular ﬁltration rate
(GFR) < 60 ml/min or  60 ml/min. A DerSimonian-Laird random-effects model was
used. The endpoint, quantiﬁed and reported as pooled risk ratio (RR) with 95%
conﬁdence interval (CI), was the CI–AKI incidence. Heterogeneity was graded using
the I2 statistic.
Results: Eight RCTs were included. A total of 143 patients (8.5%) with baseline
GFR < 60 ml/min and 112 patients (3.6%) with baseline GFR  60 ml/min developed
CI–AKI. In patients with GFR < 60 ml/min (top panel), the pooled RR indicated
a beneﬁt from statin use(RR 0.67, 95% CI 0.45–1.00, p¼0.50). In patients with GFR
 60 ml/min (bottom panel), the pooled RR indicated a highly signiﬁcant greater
beneﬁt (RR 0.40, 95% CI 0.27–0.61, p< 0.0001) from statin use. I2 was modest in the
ﬁrst analysis (27.5%) and absent in the second(0%).B74 JACC Vol 64/11/Suppl B j September 13–17Conclusions: Statins administration before coronary catheterization leads to a sig-
niﬁcant reduction in the pooled RR of CI-AKI in patients with GFR  60 ml/min.
However a reduced but persistent beneﬁt was seen also in patients with GFR < 60 ml/
min. Larger double–blind RCTs are requested to conﬁrm this results.
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Background: We evaluated the prevalence, predictors, and outcomes of patients who
developed contrast induced nephropathy (CIN) after undergoing percutaneous
vascular intervention (PVI). The association between renal function based contrast
dose and CIN was also explored.
Methods: A total of 13,126 PVI patients from 2010 to 2013 were included in the
analysis. Patients on chronic dialysis or those undergoing a PVI and open vascular
surgery procedure in the same setting were excluded. CIN was deﬁned as an increase
in serum creatinine of  0.5 mg/dl above baseline. A CIN risk model was developed
using logistic regression analysis.
Results: CIN occurred in 3% (400 patients) of the cohort and of these 6.5% (26
patients) developed the need for new dialysis. CIN was strongly associated with
adverse outcome including death (OR 40, CI 26-62.1, p < 0.001), myocardial
infarction (MI) (OR 25.8, CI 15.6-42.6, p < 0.001), TIA/stroke (OR 10.3, CI 4.4-24.2,
p < 0.001), vascular access complications (OR 4, CI 2.8-5.7, p < 0.001), and
transfusion (OR 12.6, CI 10.1-15.7, p < 0.001). Hospital stay was longer in patients
who developed CIN vs. those who did not (non-CIN) (median 9 vs. 2 days respec-
tively, p < 0.001, mean 11.6 vs. 3.8 days respectively, p < 0.001). Predictors of CIN
by logistic regression are shown in the table (Area under the ROC Curve (AUC):
0.789).min)Conclusions: CIN is a common complication associated with PVI and strongly
associated with the risk of in-hospital death, MI, stroke, transfusion and increased
hospital length of stay. Clinical predictors of CIN include high and low body weight,
diabetes, heart failure, anemia, baseline renal dysfunction, critical limb ischemia and a
higher acuity of the PVI procedure. Exceeding a contrast dose of greater than three
times the creatinine clearance was strongly associated with CIN, and suggests the need
for minimizing contrast dose in patients undergoing PVI.
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Very Low Intravenous Contrast Dose (20cc) Protocol for Computed
Tomography Angiography (CTA) Providing Comprehensive Cardiac and
Vascular Assessment for Transcatheter Aortic Valve Replacement (TAVR) in
Patients with Chronic Kidney Disease (CKD)
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Torsten P. Vahl1, Martin Leon1, Belinda Dsouza1
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Background: TAVR is a lifesaving procedure for many patients at high risk for
surgical aortic valve replacement. The prevalence of CKD and risk for contrast-
induced nephropathy in this population is high. A very low contrast dose CTA pro-
tocol enabling comprehensive cardiac and vascular imaging would be valuable in this
fragile patient population., 2014 j TCT Abstracts/Renal Insufﬁciency and Contrast Nephropathy
